Related Experiment Video
Updated: Aug 6, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Real-World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A
Shawky E L Saaty1, Hamza Salim Alshehri2, Osama Alsharif3
1Dermatology Department, East Jeddah Hospital, Jeddah, Saudi Arabia.
Background:
Upadacitinib is an oral, selective, and reversible Janus kinase inhibitor that has demonstrated sustained efficacy and safety over 140 weeks in clinical trials for treating atopic dermatitis (AD). We evaluated the real-world effectiveness and impact on quality of life (QoL) of upadacitinib-based treatment therapy in patients with moderate-to-severe AD in Saudi Arabia (SA).
Methods:
A retrospective chart review was conducted at six sites. Data were collected from medical records of patients with AD aged ≥ 12 years who were treated with upadacitinib for a period of six months.
Results:
This study included 109 AD patients, with 15.6% (17/109) being adolescents (aged 12-17) and 84.4% (92/109) being adults (aged 18 and older). The mean age was 30.9 years (57.8% males). Based on disease severity assessment by the Eczema Area and Severity Index (EASI) scoring system, severe AD was observed in 65.1% of the patients. At six months, 83.5% of the patients had an EASI score ≤ 7 and EASI-75, EASI-90, and EASI-100 were achieved by 83.5%, 57.8%, and 12.8%, respectively. Dermatology life quality index (DLQI) 0/1 and pruritus Numerical Rating Scale (NRS) 0/1 at 6 months were achieved by 28.4% and 64.2%, respectively. Improvements were observed in the EASI, DLQI, and pruritus-NRS scores from baseline to the last visit (p < 0.001). The frequency of outpatient visits and filled prescriptions among AD patients remained stable after upadacitinib initiation, with a median (range) of 2 (1-20) outpatient visits before and 2 (1-9) after 6 months and a median (range) of 2 (1-12) filled prescriptions before compared with 2 (0-14) after 6 months. Adverse events (AEs) were reported in 10 patients, with acne being the most commonly observed.
Conclusion:
Upadacitinib-based treatment strategies showed an improvement in DLQI, EASI, and pruritus-NRS scores in patients with moderate-to-severe AD in SA. No new safety signals were identified, reinforcing its favorable benefit-risk profile in AD management.
